Anticancer activities of artemisinin and its bioactive derivatives

Expert Reviews in Molecular Medicine

Volumn 11, Issue , 2009, Pages

  Firestone, Gary L ^a   Sundar, Shyam N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; APOPTOSIS REGULATORY PROTEIN; ARTEMISININ; ARTEMISININ DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53; TRANSFERRIN;

APOPTOSIS; ARTEMISIA ANNUA; CELL CYCLE; CELL MOTION; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTI-INFECTIVE AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARTEMISIA ANNUA; ARTEMISININS; CELL CYCLE; CELL MOVEMENT; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSFERRIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952795743     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399409001239     Document Type: Review

References (75)

1. Duffy, P.E. and Mutabingwa, T.K. (2004) Drug combinations for malaria: time to ACT? Lancet 363, 3-4 (Pubitemid 38076914)
2. Meshnick, S.R. (1998) Artemisinin antimalarials: mechanisms of action and resistance. Médecine Tropicale 58, 13-17
3. Efferth, T. (2009) Artemisinin: a versatile weapon from traditional Chinese medicine. In Herbal Drugs: Ethnomedicine to Modern Medicine (Ramawat, K.G., ed.), pp. 173-194, Springer-Verlag Berlin Heidelberg
4. Meshnick, S.R. (2002) Artemisinin: mechanisms of action, resistance and toxicity. International Journal for Parasitology 32, 1655-1660
5. Rosenthal, P.J. and Meshnick, S.R. (1996) Hemoglobin catabolism and iron utilization by malaria parasites. Molecular and Biochemical Parasitology 83, 131-139 (Pubitemid 27062385)
6. Efferth, T. et al. (2001) The anti-malarial artesunate is also active against cancer. International Journal of Oncology 18, 767-773
7. Paik, I.H. et al. (2006) Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. Journal of Medicinal Chemistry 49, 2731-2734
8. Bustos, M.D., Gay, F. and Diquet, B. (1994) In-vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives. Bulletin of the World Health Organization 72, 729-735 (Pubitemid 24344096)
9. Kelter, G. et al. (2007) Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One 2, e798
10. Efferth, T., Olbrich, A. and Bauer, R. (2002) mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochemical Pharmacology 64, 617-623
11. Mukanganyama, S. et al. (2002) Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. International Journal of Cancer 97, 700-705 (Pubitemid 34087813)
12. Nam, W. et al. (2007) Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head and Neck 29, 335-340 (Pubitemid 46623498)
13. Chen, H. et al. (2009) Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anti-Cancer Drugs 20, 131-140
14. Lu, Y.Y. et al. (2009) Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. Journal of Biomedical Science 16, 16
15. Hou, J. et al. (2008) Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clinical Cancer Research 14, 5519-5530
16. Jiao, Y. et al. (2007) Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacologica Sinica 28, 1045-1056 (Pubitemid 47020494)
17. Sundar, S.N. et al. (2008) Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 29, 2252-2258
18. Willoughby, J.A., Sr et al. (2009) Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. Journal of Biological Chemistry 284, 2203-2213
19. Dong, L. et al. (1999) Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. Journal of Biological Chemistry 274, 32099-32107
20. Lee, S.K. et al. (2006) p38 and ERK MAP kinase mediates iron chelator-induced apoptosis and-suppressed differentiation of immortalized and malignant human oral keratinocytes. Life Sciences 79, 1419-1427
21. Petersen, C. et al. (2005) The p38 MAPK pathway mediates interleukin-1-induced Sertoli cell proliferation. Cytokine 32, 51-59 (Pubitemid 41405784)
22. Mu, D. et al. (2008) The role of calcium, P38MAPKin dihydroartemisinin- induced apoptosis of lung cancer PC-14 cells. Cancer Chemotherapy and Pharmacology 61, 639-645
23. Riganti, C. et al. (2009) Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. British Journal of Pharmacology 156, 1054-1066
24. Genovese, R.F. and Newman, D.B. (2008) Understanding artemisinin-induced brainstem neurotoxicity. Archives of Toxicology 82, 379-385
25. Mu, D. et al. (2007) Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. Methods and Findings in Experimental and Clinical Pharmacology 29, 33-38 (Pubitemid 46447221)
26. Mita, A.C. et al. (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research. 14, 5000-5005
27. Maruyama, J. et al. (2009) Stress-activated MAP kinase cascades in cellular senescence. Current Medicinal Chemistry 16, 1229-1235
28. Efferth, T. et al. (2003) Molecular modes of action of artesunate in tumor cell lines. Molecular Pharmacology 64, 382-394 (Pubitemid 36910002)
29. Gautam, A. et al. (2009) Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Current Drug Metabolism 10, 289-306
30. Efferth, T. et al. (2004) Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radical Biology and Medicine 37, 998-1009 (Pubitemid 39164582)
31. Nakase, I. et al. (2009) Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Letters 274, 290-298
32. Mauriz, J.L., Tunon, M.J. and Gonzalez-Gallego, J. (2008) Apoptotic signaling pathways as a target for the treatment of liver diseases. Mini Reviews in Medicinal Chemistry 8, 1485-1493
33. Li, P.C. et al. (2008) Artesunate derived from traditional Chinese medicine inducesDNAdamage and repair. Cancer Research 68, 4347-4351
34. Huang, X.J. et al. (2008) Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology 82, 1-9
35. Wang, J.X. et al. (2007) Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. British Journal of Pharmacology 150, 652-661
36. Wang, Z. et al. (2007) Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. Journal of Immunology 179, 5958-5965
37. McEwan, I.J. (2009) Nuclear receptors: one big family. Methods in Molecular Biology 505, 3-18
38. Kerkhofs, S. et al. (2009) Androgen receptor knockout and knock-in mouse models. Journal of Molecular Endocrinology 42, 11-17
39. McDevitt, M.A. et al. (2008) New insights into the classical and non-classical actions of estrogen: evidence from estrogen receptor knock-out and knock-in mice. Molecular and Cellular Endocrinology 290, 24-30
40. Santen, R. et al. (2009) Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. Annals of the New York Academy of Sciences 1155, 132-140
41. Fox, E.M., Davis, R.J. and Shupnik, M.A. (2008) ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 73, 1039-1051
42. Paruthiyil, S. et al. (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Research 64, 423-428 (Pubitemid 38114127)
43. Strom, A. et al. (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proceedings of the National Academy of Sciences of the United States of America 101, 1566-1571 (Pubitemid 38236167)
44. Roger, P. et al. (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Research 61, 2537-2541 (Pubitemid 32685835)
45. Shaaban, A.M. et al. (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. American Journal of Surgical Pathology 27, 1502-1512 (Pubitemid 37486611)
46. Lai, H. and Singh, N.P. (2006) Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Letters 231, 43-48 (Pubitemid 41779452)
47. Cheng, J. et al. (2007) Tamoxifen induction of CCAATenhancer-binding protein alpha is required for tamoxifen-induced apoptosis. Journal of Biological Chemistry 282, 30535-30543 (Pubitemid 350035167)
48. Eeckhoute, J. et al. (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Research 67, 6477-6483 (Pubitemid 47037533)
49. Kerdelhue, B. and Jolette, J. (2002) The influence of the route of administration of 17beta-estradiol, intravenous (pulsed) versus oral, upon DMBA-induced mammary tumour development in ovariectomised rats. Breast Cancer Research and Treatment 73, 13-22 (Pubitemid 34548161)
50. Hung, H. (2004) Inhibition of estrogen receptor alpha expression and function in MCF7 cells by kaempferol. Journal of Cellular Physiology 198, 197-208
51. Sundar, S.N. et al. (2006) Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells. Molecular Endocrinology 20, 3070-3082 (Pubitemid 44833556)
52. Staka, C.M., Nicholson, R.I. and Gee, J.M. (2005) Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocrine-Related Cancer 12 (Suppl 1), S85-97 (Pubitemid 41395416)
53. Crawford, E.D. (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73, S4-10
54. Ghosh, P.M. et al. (2005) Signal transduction pathways in androgen-dependent and-independent prostate cancer cell proliferation. Endocrine-Related Cancer 12, 119-134 (Pubitemid 40477093)
55. Heinlein, C.A. and Chang, C. (2004) Androgen receptor in prostate cancer. Endocrine Reviews 25, 276-308 (Pubitemid 38501396)
56. Isbarn, H. et al. Testosterone and prostate cancer: revisiting oldparadigms.EuropeanUrology (in press)
57. Modica, S., Bellafante, E. and Moschetta, A. (2009) Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. Frontiers in Bioscience 14, 4719-4745
58. Masi, A.D. et al. Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Molecular Aspects of Medicine (in press)
59. Burk, O. et al. (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Molecular Pharmacology 67, 1954-1965 (Pubitemid 41007777)
60. Haslam, I.S. et al. (2008) Induction of P-glycoprotein expression and function in humanintestinal epithelial cells (T84). Biochemical Pharmacology 76, 850-861
61. Wu, X. et al. (2009) Chemokine receptors as targets for cancer therapy. Current Pharmaceutical Design 15, 742-757
62. Tischer, E. et al. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. Journal of Biological Chemistry 266, 11947-11954
63. Anfosso, L. et al. (2006) Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics Journal 6, 269-278 (Pubitemid 44137954)
64. Wartenberg, M. et al. (2003) The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Laboratory Investigation 83, 1647-1655 (Pubitemid 37421105)
65. Zhou, H.J. et al. (2007) Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascular Pharmacology 47, 131-138
66. Chen, T. et al. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. Journal of Cellular and Molecular Medicine (in press)
67. Kim, M.S. et al. (2000) Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. International Journal of Cancer 87, 269-275 (Pubitemid 30434357)
68. Jeong, S.J. et al. (2002) Costunolide, a sesquiterpene lactone from Saussurea lappa, inhibits the VEGFR KDR/Flk-1 signaling pathway. Cancer Letters 187, 129-133
69. Longo, M. et al. (2006) Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reproductive Toxicology 21, 83-93 (Pubitemid 43048778)
70. Buommino, E. et al. (2009) Artemisinin reduces human melanoma cell migration by down-regulating alphaVbeta3 integrin and reducing metalloproteinase 2 production. Investigational New Drugs 27, 412-418
71. Hung, W.C. and Chang, H.C. (2009) Indole-3-carbinol inhibits Sp1-induced matrix metalloproteinase-2 expression to attenuate migration and invasion of breast cancer cells. Journal of Agricultural and Food Chemistry 57, 76-82
72. Fishwick, J. et al. (1995) The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. Chemico-Biological Interactions 96, 263-271
73. Efferth, T. et al. (2004) Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochemical Pharmacology 67, 1689-1700 (Pubitemid 38479847)
74. Harichand-Herdt, S., Zelnak, A. and O'Regan, R. (2009) Endocrine therapy for the treatment of postmenopausal women with breast cancer. Expert Review of Anticancer Therapy 9, 187-198
75. Rau, K.M. et al. (2005) The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocrine-related Cancer 12, 511-532